Spyre Therapeutics Inc.
SYRE | NASDAQ
$91.91
-$0.12 (-0.13%)
Sep 22, 2026, 11:17 AM ET · Market open
Market Data
Market Cap $7.99B
Enterprise Value $6.85B
Beta 3.00
Average Volume 1.25M
Shares Outstanding (Diluted) 84.73M
Shares Change YoY 39.6%
Institutional Ownership N/A
Exchange NASDAQ
ISIN US00773J2024
Price Performance
Price Change 1M -13.6%
Price Change 3M -5.2%
Price Change 6M 101.5%
Price Change YTD 200.9%
Price Change 1Y 501.9%
Price Change 3Y 676.0%
Price Change 5Y -52.0%
1M CAGR (ann.) -12.3%
1Y CAGR (ann.) 500.7%
5Y CAGR (ann.) -11.9%
All-Time CAGR -8.9%
Valuation
PE Ratio -47.19
Forward PE N/A
PEG Ratio 0.92
Forward PEG -1.49
PS Ratio 88.32
Forward PS 47,951.90
PB Ratio 7.26
P/FCF Ratio -38.25
P/Adj. FCF Ratio -31.39
P/OCF Ratio -37.26
EV/Sales 75.66
EV/EBIT -36.90
EV/EBITDA -36.90
EV/FCF -32.77
Earnings Yield -2.1%
FCF Yield -2.6%
Adj. FCF Yield -3.2%
Financial Health
Net Cash $1.15B
Total Debt $0
Cash & Short-Term Investments $1.15B
Total Assets $1.17B
Current Ratio 18.53
Quick Ratio 18.53
Debt / Equity Ratio 0.00
Debt / EBITDA -0.00
Debt / FCF -0.00
OCF / Debt N/A
Interest Coverage 0.00
Altman Z-Score 65.95
Piotroski F-Score 3
Margins & Profitability
Gross Profit Margin 0.0%
Operating Profit Margin -222.5%
EBITDA Margin -205.1%
Net Profit Margin -197.7%
FCF Margin -230.9%
Adj. FCF Margin -281.4%
SBC / Revenue 50.5%
SBC Impact (per share) -21.9%
Returns
Return on Assets -15.3%
Return on Equity -24.3%
Return on Invested Capital -18.1%
Return on Capital Employed -18.1%
Return on Tangible Assets -15.3%
Historical Growth (CAGR)
Revenue CAGR 3Y 319.3%
Revenue CAGR 5Y 45.9%
Revenue CAGR 10Y 33.9%
EPS CAGR 3Y 100.2%
EPS CAGR 5Y 53.8%
EPS CAGR 10Y 14.6%
FCF CAGR 3Y -15.2%
FCF CAGR 5Y -25.2%
FCF CAGR 10Y -20.7%
Analyst Forecasts
Analyst Rating Buy
Analyst Count 13
EPS Growth Next 3Y -42.7%
Revenue Growth Next 3Y 1.0%
Earnings Date Nov 2, 2026
EPS Estimate (next Q) -$0.80
EPS Growth Est (next Q) 433.3%
Revenue Est (next Q) N/A
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $111.82
Price Target Upside 21.5%
Cash Flow
Operating Cash Flow $-208.94M
Free Cash Flow $-208.94M
Adj. Free Cash Flow $-254.64M
FCF Per Share -$2.47
OCF Per Share -$2.47
OCF/S Ratio -230.9%
Income Statement
Revenue $90.49M
Gross Profit $0
Operating Income $-201.34M
EBITDA $-185.55M
Net Income $-178.92M
EPS (Diluted) -$1.95
Revenue / Employee $723.95K
Profit / Employee $-1.43M
Employees 125
Add to Watchlist
Select watchlists to add or remove SYRE